Calidi Biotherapeutics Establishes Scientific Advisory Board for RedTail Platform
Meno di 1 minuto di lettura
On October 22, 2025, Calidi Biotherapeutics announced the formation of a new scientific advisory board to advance its RedTail platform.
Key Highlights:
- New board to enhance RedTail platform development.
- Focus on advancing CLD-401 into clinical trials.
- RedTail uses engineered virus for targeted delivery.
- CLD-401 targets metastatic sites, induces immune response.
- Board includes experts in oncology and virotherapy.
Original SEC Filing: Calidi Biotherapeutics, Inc. [ CLDI ] - 8-K - Oct. 24, 2025
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.